In general, the present research showed a novel strong dual inhibitor of AChE and BuChE (BOP-1) and a new selective potent anti-AChE agent (BOP-8) with a potential therapeutic advantage and further research value for the treatment of AD. Here, ACHE is linked to Alzheimer disease.